Squeeze Report — July 23, 2026
Today's squeeze landscape is a study in extremes: a single high-conviction biotech (SRRK) faces a binary FDA facility decision that could ignite a 19% short interest, while the rest of the field is littered with low-confidence setups undermined by cheap borrow, declining short positions, or overwhelming dilution. The clustering of Q2 earnings catalysts across ACDC, IOVA, and STEP offers potential for event-driven pops, but only where insider buying or a tiny float can overcome the prevailing regime of contracting squeeze pressure.
Today's top short-squeeze candidates
- #1VSTMVerastem, Inc. Common Stock66
A 45.6% short interest is a mirage: a going-concern warning and 12.2M pre-funded warrants will absorb any squeeze.
SI 46%DTC 7.0$5.89+40% 20dHealthcare - #2SRRKScholar Rock Holding Corporati66
A pending FDA facility reclassification is the binary key to unlocking a 19.1% short interest with 7.2 days to cover.
SI 19%DTC 7.2$48.30-6% 20dHealthcare - #3IOVAIovance Biotherapeutics, Inc.64
A record Amtagvi quarter could squeeze 33.5% short interest, but cheap borrow and 43% share dilution keep the risk elevated.
SI 34%DTC 7.1$5.17+16% 20dHealthcare - #4AGENAgenus Inc. Common Stock62
A $340M financing deal erased bankruptcy risk, but stale short data may already reflect covering after the 80% surge.
SI 16%DTC 5.4$5.53+80% 20dHealthcare - #5ABRArbor Realty Trust, Inc.58
A 23% short interest and 11.45 days to cover are undermined by a dividend cut and near-$1B in non-performing assets.
SI 23%DTC 11.4$5.04-1% 20dReal Estate - #6XXITwenty One Capital, Inc.57
A 45.6% short interest in a tiny float is negated by a CEO exit, collapsed merger, and massive convertible-note overhang.
SI 46%DTC 3.0$5.02-12% 20dFinancial Services - #7RZLTRezolute, Inc. Common Stock (N54
A 24.9% short interest awaits binary Phase 3 data, but cheap borrow and a prior trial failure keep shorts entrenched.
SI 25%DTC 5.8$5.00+2% 20dHealthcare - #8ACDCProFrac Holding Corp. Class A50
A 38.5% short-interest surge and seven insider buys set the stage, but Q2 earnings must reverse a 25% revenue drop to trigger it.
SI 47%DTC 3.3$5.06-16% 20dEnergy - #9NUAINew Era Energy & Digital, Inc.50
Extreme 43% short interest is mechanically un-squeezable given 1.87 days to cover and a mandated ATM dilution overhang.
SI 43%DTC 1.9$5.81-6% 20dEnergy - #10WHWyndham Hotels & Resorts, Inc.46
Short interest is declining, options show no squeeze premium, and the next earnings catalyst is over three months away.
SI 9%DTC 4.3$75.68-11% 20dConsumer Cyclical - #11ACHRArcher Aviation Inc.42
A 0.32% borrow fee and declining short interest defang the 17.1% short position, with no FAA catalyst in sight.
SI 17%DTC 2.6$5.18-1% 20dIndustrials - #12ACADACADIA Pharmaceuticals Inc. Co41
Declining short interest and negligible borrow fees make a squeeze unlikely, even if Q2 earnings beat the lowered bar.
SI 6%DTC 4.8$24.96+10% 20dHealthcare - #13STEPStepStone Group Inc. Class A C39
A low-float structure and $100M buyback could amplify an earnings beat, despite short interest actually declining.
SI 5%DTC 2.9$41.11-4% 20dFinancial Services - #14FTAIFTAI Aviation Ltd. Common Stoc35
A $61.5M director sale and three consecutive EPS misses overwhelm any squeeze case from a modest 6.1% short interest.
SI 6%DTC 5.6$222.49-15% 20dIndustrials - #15TXTTextron, Inc.35
A 3.7% short interest and declining positions in a large-cap industrial offer no credible squeeze catalyst.
SI 4%DTC 3.2$91.71+6% 20dIndustrials
See the full ranked board
This is the top sliver of 15 names we rank every day. The live board carries rank history, days-to-cover fuel gauges, AI research, and a backtested signal validator.
Open the live squeeze board →